Reggio Emilia, Italy – After decades of misdiagnosis and unanswered questions, a 52-year-aged woman has finally received a diagnosis for a rare genetic condition that has plagued her and her family for generations. The breakthrough, achieved at the Immunologia Oculare department of the AUSL-IRCCS of Reggio Emilia, began with a seemingly isolated case of uveitis – inflammation of the eye – and ultimately revealed a hereditary amyloidosis, a condition characterized by the buildup of abnormal proteins in organs and tissues. This discovery not only offers the patient access to experimental therapies but also allows her to alert family members, potentially preventing further illness and saving lives.
The patient, of Albanian origin, had been seeking answers for years, undergoing numerous tests across Italy and Europe without a conclusive diagnosis. Her case initially presented as uveitis in October 2025, prompting a referral to the Reggio Emilia hospital. However, specialists Dr. Luca De Simone and Professor Luca Cimino suspected a more systemic issue, recognizing the potential for a multi-organ pathology based on the ocular presentation. This initial suspicion proved pivotal in unraveling a complex medical mystery.
The diagnostic process involved a vitrectomy, a surgical procedure to remove the vitreous humor from the eye, allowing for detailed analysis. This led to the identification of hereditary transthyretin amyloidosis (hATTR), a rare and often fatal genetic disorder. The Mayo Clinic describes hATTR as a condition where a mutated transthyretin protein misfolds and accumulates, damaging organs like the heart, nerves, and kidneys.
A Family History of Unexplained Illness
The significance of the diagnosis extends beyond the individual patient. The patient’s family history revealed a pattern of unexplained illnesses and premature deaths over the past three decades, strongly suggesting a genetic link. The identification of hATTR provides a framework for understanding these past tragedies and offers a path toward preventative care for at-risk relatives. Currently, genetic screening of family members is underway to identify those who carry the mutation and may benefit from early intervention.
“The experience highlights the importance of integrated care models and interdisciplinary pathways in the diagnosis of rare diseases and the role of the ophthalmologist in the early identification of ocular signs indicative of pathologies that can affect different parts of the body,” stated a note from the AUSL, as reported by AUSL-IRCCS of Reggio Emilia. The case underscores the critical role of specialized departments like Immunologia Oculare in recognizing subtle clues that can lead to the diagnosis of complex and rare conditions.
The Role of Immunologia Oculare in Rare Disease Detection
The Immunologia Oculare department at the AUSL-IRCCS of Reggio Emilia has established itself as a key center for diagnosing complex inflammatory eye diseases and identifying potential indicators of underlying rare conditions. The department’s expertise in this area proved crucial in recognizing the systemic nature of the patient’s illness and pursuing a comprehensive diagnostic workup. Dr. Marco Vecchi, Director of the Oculistica department, played a key role in the diagnostic intervention on the eye.
Hereditary transthyretin amyloidosis is a progressive disease, and early diagnosis is critical for managing symptoms and potentially slowing its progression. While there is currently no cure, treatments are available to manage the condition and improve quality of life. The patient’s access to experimental therapies offers a glimmer of hope, and the ongoing family screening program promises to prevent further suffering within the family.
Commitment to Rare Disease Research and Treatment
The AUSL-IRCCS of Reggio Emilia has reaffirmed its commitment to developing diagnostic and therapeutic pathways for rare diseases. This commitment is demonstrated through the integration of specialized clinical assistance, research activities, and collaboration between professionals across different departments. This collaborative approach is essential for understanding and addressing the complexities of rare diseases, which often require a multidisciplinary perspective.
The case serves as a powerful reminder of the challenges faced by individuals with rare diseases and the importance of continued investment in research and specialized care. The successful diagnosis in Reggio Emilia offers a beacon of hope for other families grappling with similar mysteries and underscores the potential for breakthroughs when expertise and collaboration converge.
The genetic screening of the patient’s family is ongoing, and results are expected to be available in the coming months. The AUSL-IRCCS of Reggio Emilia will continue to monitor the patient’s progress and provide updates as they become available. For more information on hereditary transthyretin amyloidosis, resources are available through the Amyloidosis Foundation.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by a rare disease? Share your story or leave a comment below.
